StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Price Performance

Shares of NASDAQ:LPCN opened at $5.10 on Friday. The business’s 50 day moving average price is $5.10 and its 200-day moving average price is $5.57. Lipocine has a 1 year low of $2.40 and a 1 year high of $11.79. The firm has a market capitalization of $27.27 million, a price-to-earnings ratio of -6.71 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Lipocine will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.